国立研究開発法人 国立成育医療研究センター National Center for Child Health and Development

代表: 03-3416-0181 / 予約センター(病院): 03-5494-7300
〈月~金曜日(祝祭日を除く)9時〜17時〉

  • アクセス・交通案内
  • 予約センター
  • MENU

研究者・企業の方へ Scholar & Enterprise

研究者・企業の方へ Scholar & Enterprise

論文

氏名:横谷 進

主な論文・総説・著書
1 Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, Hizuka N, Teramoto A, Tatsumi KI, Tachibana K, Katsumata N, Horikawa R: Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J. 2012 Sep 30;59(9):771-80
2 Isojima T, Yokoya S, Ito J, Horikawa R, Tanaka T: New reference growth charts for Japanese girls with Turner syndrome. Pediatr Int 2009;51:709-714
3 Yokoya S, Araki K, Igarashi Y, Kohno H, Nishi Y, Hasegawa Y, Fujita K, Iwatani N, Tachibana K, Ohyama Y, Seino Y, Satoh M, Fujieda K, Tanaka T: High-dose growth hormone (GH) treatment in prepubertal GH-deficient children. Acta Paediatr 1999;88:76-79
4 Yokoya S, Suwa S, Maesaka H, Tanaka T: Immunoreactive somatomedin C/insulin-like growth factor I in urine from normal subjects, pituitary dwarfs, and acromegalics. Pediatr Res. 1988;23(2):151-154
5 Yokoya S, Friesen HG: Human growth hormone (GH)-releasing factor stimulates and somatostatin inhibits the release of rat GH variants. Endocrinology 1986 ;119(5):2097-2105
6 横谷進,落合亮太,小林信秋,駒松仁子,増子孝徳,水口雅,南砂,八尾厚史(日本小児科学会 移行期の患者に関するワーキンググループ)小児期発症疾患を有する患者の移行期医療に関する提言.日本小児科学会雑誌 2014;118: 98-106
7 横谷進,西美和,河野斉,安達昌功,石黒寛之,大竹明,田島敏広,藤原幾磨,堀川玲子,有瀧健太郎,三善陽子,依藤亨(日本小児内分泌学会CCS委員会):小児がん経験者(CCS)のための内分泌フォローアップガイド.日本小児科学会雑誌2012; 116(12): 1976-1977
8 横谷進, 依藤亨, 田中敏章(日本小児内分泌学会成長ホルモン委員会). 成長ホルモン分泌不全性低身長症の小児期の成長ホルモン治療から成人期の成長ホルモン治療への移行ガイドライン. 日本小児科学会雑誌 2006;110:1475-9
9 横谷進, 伊藤令子, 佐藤真理, 田中敏章, 佐藤亨至. チャート法(projected height SDスコア法)による最終身長予測-5歳以降の全年齢層における予測の有用性の検討-. 日本小児科学会雑誌 1998; 102:34-40
10 横谷進, 徳弘悦郎, 前坂機江, 諏訪?三. 少量vasopressinに対する尿濃縮反応-正常者,中枢性尿崩症,腎性尿崩症とその家族、両側性膀胱尿管逆流,下垂体前葉機能低下症における検討. 日本小児科学会雑誌 1987;91:1414-1420

氏名:斉藤 和幸

主な論文・総説・著書
1 臨床倫理学(訳本)、朝倉書店
2 Hikoichiro M, Takatoshi N, Kazuyuki S, Regulation of traditional herbal medicinal products in Japan. Journal of Ethnopharmacology. 2014;158:511-515.

氏名:森 臨太郎

主な論文・総説・著書
1 Vogel JP, Souza JP, Gulmezoglu AM, Mori R, Lumbiganon P, Qureshi Z, Carroli G, Laopaiboon M, Fawole B, Ganchimeg T, Zhang J, Torloni MR, Bohren M, Temmerman M, for the WHO Multi-Country Survey on Maternal and Newborn Health Research Network. Use of antenatal corticosteroids and tocolytic drugs in preterm births in 29 countries: an analysis of the WHO Multicountry Survey on Maternal and Newborn Health. The Lancet. 2014;384(9957):1869 - 1877
2 Tobe-Gai R, Mori R, Huang L, Xu L, Han D and Shibuya K. Cost-effectiveness analysis of a national neonatal hearing screening program in China: Universal or targeted strategy? PLoS ONE. 8(1): e51990.
3 Mori R, Ota E, Middleton P, Tobe-Gai R, Mahomed K, Bhutta ZA. Zinc supplementation for improving pregnancy and infant outcome. Cochrane Database of Systematic Reviews 2012;7:CD000230
4 Mori R, Takemi K, and Fineberg H. Science and consensus for health policy making in Japan. Lancet. 2012;379(9810):12-13
5 Mori R, Nardin JM, Yamamoto N, Carroli G and Weeks AD. Umbilical vein injection for the routine management of third stage of labour. Cochrane Database of Systematic Reviews. 2012;3:CD006176.
6 Nagai S, Andrianarimanana D, Rabesandratana N, Yonemoto N, Nakayama T, and Mori R. Long-term Effects of Earlier Initiated Continuous Kangaroo-Mother-Care (KMC) for Low-Birth-Weight (LBW) infants in Madagascar. Acta Paediatrica. 2011;100(12):e241-e247.
7 Mori R, Kusuda S, Fujimura M, on behalf of Neonatal Research Network of Japan. Antenatal corticosteroids promote survival of extremely preterm infants born at 22-23 weeks of gestation. The Journal of Pediatrics. 2011;159(1):110-114.
8 Lumbiganon P, Laopaiboon M, Gulmezoglu AM, Souza JP, Taneepanichskul S, Ruyan P, Attygalle DE, Shrestha N, Mori R, Hinh ND, Bang HT, Rathavy T, Chuyun K, Cheang K, Festin M, Udomprasertgul V, Germar MJV, Yanqui G, Roy M, Carroli G, Ba-Thike K, Filatova E, and Villar J. Mode of delivery and pregnancy outcomes in Asia: The WHO Global Survey on Maternal and Perinatal Health 2007-2008. Lancet. 2010;375(9713):490-499.
9 Mori R, Dougherty M, and Whittle M. An estimation of intrapartum-related perinatal mortality rates for booked home births in England and Wales between 1994 and 2003. BJOG. 2008;115(5):554-559.
10 Mori R, Lakhanpaul M, and Verrier-Jones K. Diagnosis and management of urinary tract infection in children: summary of NICE guidance. BMJ 2007;335:397-397.

氏名:石黒 精

主な論文・総説・著書
1 Yotani N, Ishiguro A, Sakai H, et al, Factor-associated caregiver burden in medically complex patients with special health care needs. Pediatr Int 2014;56:742-747.
2 Minowa K, Arai K, Ishiguro A, et al, Romiplostim treatment allows for platelet transfusion-free liver transplantation in pediatric thrombocytopenic patient with primary sclerosing cholangitis. Pediatr Transplant, 2014;18:E212-5.
3 Fujimaru T, Ito S, Ishiguro A, et al, Decreased levels of inflammatory cytokines in immunoglobulin-resistant Kawasaki disease after plasma exchange. Cytokine 2014;70:156-60.
4 Maekawa T, Oba M, Ishiguro A, et al, Modified pulmonary index score was sufficiently reliable to assess the severity of acute asthma exacerbations in children. Allergol Int 2014;63:603-607.
5 Ishiguro A, Nakahata T, Matsubara K, et al, Age-related changes in thrombopoietin in children: reference interval for serum thrombopoietin levels. Br J Haematol 1999;106:884-888.
6 Ishiguro A, Ishikita T, Shimbo T, et al, Elevation of serum thrombopoietin precedes thrombocytosis in Kawasaki disease. Thromb Haemost 1999;79:1096-1099.
7 Ishiguro A, Suzuki Y, Inaba Y, et al, Production of interleukin 10 in the cerebrospinal fluid in aseptic meningitis of children. Pediatr Res 1997;40:610-613.
8 Ishiguro A, Spirin K, Shiohara M, et al, Id2 expression increases with myeloid differentiation in human myeloid cells. Blood 1997;87::5225-5230.
9 Nakahata T, Kobayashi T, Ishiguro A, et al, Extensive proliferation of mature connective-tissue type mast cells in vitro. Nature 1986;324:65-67.
10 石黒 精,嶋 緑倫,瀧 正志,他(編),はじめての血友病診療実践マニュアル.東京,診断と治療社,2012.

氏名:中村 秀文

主な論文・総説・著書
1 Tsukamoto K, Carroll KA, Onishi T, Matsumaru N, Brasseur D, Nakamura H: Improvement of Pediatric Drug Development:Regulatory and Practical Frameworks. Clinical Therapeutics 2016 Mar;38(3):574-81.
2 Kamei K, Sako M, Ishikawa T, Sato M, Ogura M, Uno T, Kiyotani C, Mori T, Tanaka H, Ito S, Nakamura H.; Pharmacokinetics of Carboplatin in a One-Year-Old Anuric Boy Undergoing Hemodialysis and a Review of the Literature. Ther Apher Dial. 2015;
Oct;19(5):491-6. doi: 10.1111/1744-9987.12302. Epub 2015 Apr 27.
3 Iijima K, Sako M, Nozu K,,, Nakamura H, et al: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 2014;384(9950) October 2014: 1273 - 1281
4 Yoshikawa N, Nakanishi K, Sako M,,, Nakamura H, et al: A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment. Kidney Int 2014 Jul 23. doi: 10.1038/ki.2014.260. [Epub ahead of print]
5 Nakamura H, Ishikawa Y: How do Japanese children take their medicines, and what are pharmacists and paediatricians doing about it? Int. J. of Pharmaceutics. 04/2014; DOI: 10.1016/j.ijpharm.2014.03.053
6 Amstutz U1, Shear NH, Rieder MJ,,, Nakamura H, et al: Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014; Mar 5. doi: 10.1111/epi.12564. [Epub ahead of print]
7 Iijima K, Sako M, Saito Oba M,,, Nakamura H, et al; Cyclosporine C2 Monitoring for the Treatment of Frequently Relapsing Nephrotic Syndrome in Children:A Multicenter Randomized Phase II Trial. Clinical Journal of the American Society of Nephrology 2014;9(2):1-8
8 Nakamura H, Osawa M, Yokoyama T, et al: Efficacy and safety of levetiracetam as adjunctive therapy in Japanese children with uncontrolled partial-onset seizures: multicenter and open-label study (N01223), short term evaluation. Brain Nerve 2013 ; Sep;65(9):1083-92
9 Nakamura H, Kawashima H, Azuma R, et al: Pharmacokinetics of the H2 Blocker Roxatidine acetate Hydrochloride in Pediatric Patients,inComparison with Healthy Adult Volunteers. Drug Metab.Pharmacokinet 2012;27(4):422-429
10 中村秀文: 薬物投与の基本的考え方. 編集 五十嵐隆. 小児科学改訂. 第10版. 東京. 文光堂. 2011; 1067-1080

氏名:中川 聡

主な論文・総説・著書
1 Imai Y, Nakagawa S, Ito Y, Kawano T, Slutsky AS, Miyasaka K. Comparison of lung protection strategies using conventional and high-frequency oscillatory ventilation. J Appl Physiol 91:1836-1844, 2001.
2 Trachsel D, McCrindle, Nakagawa S, Bohn D. Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure. Am J Respir Crit Care Med 172:206-211, 2005.
3 Kitano Y, Nakagawa S, Kuroda T, et al. Liver position in fetal congenital diaphragmatic hernia retains a prognostic value in the era of lung-protective strategy. J Pediatr Surg 40:1827-32; 2005.
4 Okumura A, Nakagawa S, Kawashima H, et al. Deaths associated with pandemic (H1N1) 2009 among children, Japan, 2009-2010. Emerging Infectious Diseases 2011; 17:1993-2000.
5 Imamura T, Nakagawa S, Goldman RD, Fujiwara T. Validation of pediatric index of mortality 2 (PIM2) in a single pediatric intensive care unit in Japan. Intensive Care Med 2012; 38:649-654.
6 Tokuhira N, Shime N, Inoue M, Kawasaki T, Sakurai Y, Kurosaka N, Ueta I, Nakagawa S. Mechanically ventilated children with 2009 pandemic influenza A/H1N1, Results from the national pediatric intensive care registry in Japan. Pediatr Crit Care Med 2012; 13:E294-98.
7 Takeda S, Kotani T, Nakagawa S, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) severe respiratory failure in Japan. J Anesth 2012; 26:650-57.
8 Shime N, Kawasaki T, Saito O, Akamine Y, Toda Y, Takeuchi M, Sugimura H, Sakurai Y, Iijima M, Ueta I, Shimizu N, Nakagawa S. Incidence and risk factors for mortality in paediatric severe sepsis, results from national paediatric intensive care registry in Japan. Intensive Care Med 2012; 38:1191-97.
9 Nakagawa S, Shime N. Respiratory rate criteria for pediatric systemic inflammatory response syndrome. Pediatr Crit Care Med 2014; 15:182.
10 中川 聡.HFOと肺損傷予防.In 中川 聡編.HFOV(高頻度振動換気法)のすべて.東京.日刊工業新聞社2010;1-20. 中川 聡.小児医療におけるHFO.In 中川 聡編.HFOV(高頻度振動換気法)のすべて.東京.日刊工業新聞社2010;74-93.

氏名:小林 徹

主な論文・総説・著書
1 Kobayashi T, et al. A new Z-Score curve of the coronary arterial internal diameter using the Lambda-Mu-Sigma method in a pediatric population. J Am Soc Echocardiograph. 2016 in press.
2 Shiba N, Kobayashi T, et al. High PRDM16 expression identifies a poor prognostic subgroup of pediatric acute myeloid leukemia correlated to FLT3-ITD, MLL-PTD, and NUP98-NSD1: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Br J Haematol. 2016;172:581-591.
3 Tanoshima M, Kobayashi T, et al. Risks of congenital malformations in offspring exposed to valproic acid in utero: A systematic review and cumulative meta-analysis. Clin Pharmacol Ther. 2015;98:417-441.
4 Kobayashi T, et al. Efficacy of intravenous immunoglobulin combined with prednisolone for resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr. 2013;163:521-526.
5 Onouchi Y, Kobayashi T, et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012;44:517-521.
6 Kobayashi T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease: a prospective, randomised, open, blinded-endpoint trial. LANCET, 2012;379:1613-1620.
7 Kanai T, Kobayashi T, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease. Circulaion 2011;124:2822-2828.
8 Kobayashi T, et al. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy for Kawasaki disease. Pediatr Infect Dis J. 2009;28:498-502.
9 Kobayashi T, et al.. Increased CD11b expression on polymorphonuclear leucocytes and cytokine profiles in patients with Kawasaki disease. Clin Exp Immunol. 2007;148:112-118.
10 Kobayashi T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006; 113:2606-2612.

氏名:阿部 浩之

主な論文・総説・著書
1 Abe H, Morikawa R, Otsuka M. Adsorption kinetic and mechanistic studies for pharmaceutical spherical carbon adsorbents: comparison of a brand product and two generics. Colloids Surf B Biointerfaces, 103, 538-43 (2013).
2 Otsuka Y, Yamamoto M, Abe H, Otsuka M. Effects of polymorphic transformation on pharmaceutical properties of direct compressed tablets containing theophylline anhydrate bulk powder under high humidity. Colloids Surf B Biointerfaces, 102, 931-6 (2012).
3 Abe H, Otsuka M. Comparison of physico-chemical characteristics among three pharmaceutical spherical carbon adsorbents. Colloids Surf B Biointerfaces, 100, 90-4 (2012).
4 Teraoka R, Abe H, Sugama T, Ito K, Aburada M, Otsuka M. Nondestructive prediction of oren extract powder, a herbal medicine, in suppositories by chemometric near-infrared spectroscopy. J Nat Med, 66, 329-32 (2012).
5 Abe H, Otsuka M. Effects of lubricant-mixing time on prolongation of dissolution time and its prediction by measuring near infrared spectra from tablets. Drug Dev Ind Pharm, 38, 412-9 (2012).
6 Sakurai M, Abe H, Okamura N, Inoue Y, Akiyoshi T, Matsuyama K, Uchida T, Otsuka M. Stability of gabexate mesilate products: Influence of the addition of mannitol. Biomed Mater Eng, 20, 13-20 (2010).
7 Otsuka E, Abe H, Aburada M, Otsuka M. Nondestructive prediction of the drug content of an aspirin suppository by near-infrared spectroscopy. Drug Dev Ind Pharm, 36, 839-44 (2010).

氏名:佐古 まゆみ

主な論文・総説・著書
1 Kamei K, Ogura M, Sato M, Sako M, et al: Risk factors for relapse and long-term outcome in steroid-dependent nephrotic syndrome treated with rituximab. Pediatr Nephrol. 2016 ;31(1):89-95.
2 Higa A, Shima Y, Hama T, Sato M, et al: Long-term outcome of childhood IgA nephropathy with minimal proteinuria.Pediatr Nephrol. 2015;30(12):2121-2127.
3 Ogawa R, Mori R, Sako M, et al: Drug treatment for bronchopulmonary dysplasia in Japan: questionnaire survey.Pediatr Int. 2015;57(1):189-192.
4 Ishikura K, Matsumoto S, Sako M, et al: Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol, 2015 ;19(1):6-33.
5 Kaku Y, Ohtsuka Y, Sako M, et al: Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy. Clin Exp Nephrol, 2015 ;19(1):34-53.
6 Igarashi T, Ito S, Sako M, et al: Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol, 2014; 18(4): 525-557.
7 Iijima K, Sako M, Nozu K, et al: Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group: Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial.  Lancet 2014;4:1273-1281.
8 Yoshikawa N,Nakanishi K,Sako M,et al: A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.  Kidney Int 2014 Jul 23. doi: 10.1038/ki.2014.260. [Epub ahead of print]
9 Iijima K, Sako M, Oba MS, et al: Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial. Clin J Am Soc Nephrol 2014;9:271-278.
10 Sako M, Nakanishi K, Obana M, et al: Analysis of NPHS1, NPHS2, ACTN4, and WT1 in Japanese patients with congenital nephrotic syndrome. Kidney Int 2005 ;67:1248-1255.

氏名:石川 洋一

主な論文・総説・著書
1 石川洋一:小児製剤に求めること,薬剤学,Vol.75(1),28-31,2015
2 石川洋一:小児の医薬品誤飲と包装に望むこと,PHARM TECH JAPAN,Vol.30(4),623-627,2014
3 石川洋一(監・編),林昌洋(監):妊婦・授乳婦と薬,株式会社じほう,2013
4 石川洋一:母乳と妊娠・胎児の薬理学,Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases( JCS2012)96-111,2012
5 石川洋一:薬物療法とインフォームドコンセント 小児医療とインフォームドコンセント白幡聡編,68-100,医薬ジャーナル社,2010
6 石川洋一,矢作尚久,小村誠:インターネットからの薬剤情報収集,小児内科,42増刊号,91-94,2010 
7 石川洋一:新生児薬物療法の特殊性「新生児における調剤と注意点」,周産期医学,39(12),1647-1651,2009.
8 石川洋一(監):小児科領域の薬剤業務ハンドブック,株式会社じほう,2008
9 石川洋一,古川裕之,小出大介,大津洋,木内貴弘:電子カルテ導入病院における治験実施の現状と課題,日本病院薬剤師会雑誌,42(12):1577-1580,2006
10 石川洋一:小児薬物療法におけるデータネットワーク研究の取り組み.日本病院薬剤師会雑誌.41(10),1213-1218,2005

氏名:栗山 猛

主な論文・総説・著書
1 栗山猛,松井陽.未承認薬を減らす小児治験ネットワーク-より有効でより安全な医薬品を子どもたちへ.医学のあゆみ.2011;238(2),201-207.
2 栗山猛.小児医薬品開発の推進-小児治験ネットワークの構築・稼働-.医薬品医療機器レギュラトリーサイエンス2012;43(2):98-103
3 栗山猛.現場発の小児医薬品開発-より有効でより安全な医薬品を子どもたちへ-.一般財団法人日本医薬情報センターJAPIC NEWS.2013.10;354:12-13

氏名: 井上 永介

主な論文・総説・著書
1 Uno H, Claggett B, Tian L, Inoue E, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014 Aug 1;32(22):2380-2385.
2 Tsuta K, Kawago M, Inoue E, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer. 2013 Sep;81(3):371-376.
3 Urano W, Taniguchi A, Inoue E, et al. Effect of genetic polymorphisms on development of gout. J Rheumatol. 2013 Aug;40(8):1374-1378.
4 Shidara K, Inoue E, Hoshi D, et al. The influence of individual joint impairment on functional disability in rheumatoid arthritis using a large observational database of Japanese patients. J Rheumatol. 2012 Mar;39(3):476-480.
5 McCulloch CE, Searle SR, Neuhaus JM. (土居正明, 横道洋司, 青山淑子, 五百路徹也, 中村竜児, 吉田和生, 白岩健, 松下勲, 西山毅, 井上永介, 上原秀昭, 山口亨, 酒井美良 訳) 線形モデルとその拡張. 株式会社シーエーシー 2011

氏名:田島 康則

主な論文・総説・著書
1 田島康則:治験実施計画書からの逸脱、被験者の選定について,薬理と治療,2015;43(6):744-747

氏名:瀧本 哲也

主な論文・総説・著書
1 Sekimizu M, Mori T, Kikuchi A, Mitui T, Sunami S, Kobayashi R, Fujita N, Inada H, Takimoto T, Moriya Saito A, Watanabe T, Fujimoto J, Nakazawa A, Ohshima K, Horibe K, Tsurusawa M for the lymphoma committee of the Japanese Pediatric Leukemia/Lymphoma Study Group : Prognostic impact of cytogenetic abnormalities in children and adolescents with mature B-cell non-Hodgkin lymphoma:a report from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG). Pediatr Blood Cancer 62, 1294-1296, 2015.
2 Tsurusawa M, Gosho M, Mori T, Mitsui T, Sunami S, Kobayashi R, Fukano R, Tanaka F, Fujita N, Inada H, Koh K, Takimoto T, Saito A, Fujimoto J, Nakazawa A, Horibe K; for the lymphoma committee of the Japanese Pediatric Leukemia/lymphoma Study Group :Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.  Pediatr Blood Cancer 62, 279-284, 2015.
3 Limin Yang, Tetsuya Takimoto and Junichiro Fujimoto : Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma. BMC Cancer 14, 654-660, 2014.
4 Ryoji Kobayashi,Tetsuya Takimoto,Atsuko Nakazawa,Naoto Fujita,Ayumi Akazai,Kazumi Yamato,Makoto Yazaki,Takao Deguchi,Yoshiko Hashii,Koji Kato,Naoki Hatakeyama,Keizo Horibe,Hiroki Hori,Megumi Oda and Lymphoma Committee, Japanese Association of Childhood Leukemia Study: Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia: long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols. Int J Hematol 99, 743-749, 2014.
5 Masahito Tsurusawa, Tetsuya Mori, Akira Kikuchi, Tetsuo Mitsui, Shosuke Sunami, Ryoji Kobayashi, Tetsuya Takimoto, Akiko Saito, Tomoyuki Watanabe, Junichiro Fujimoto, Atsuko Nakagawa, Kouichi Ohshima, and Keizo Horibe, for the Lymphoma committee of the Japanese Pediatric Leukemia/Lymphoma Study Group : Improved treatment results of children with B-cell non-Hodgkin lymphoma: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. Pediatr Blood Cancer 61, 1215-1221,2014.
6 Tatsuo Kuroda, Ken Hoshino, Shunsuke Nosaka, Yohko Shiota, Atsuko Nakazawa, Tetsuya Takimoto :Critical hepatic hemangiomas in infants: from the results of a recent nationwide survey in Japan.Pediatr Int 56, 304-308, 2014.
7 瀧本哲也 : 疫学. 日本小児血液・がん学会(編集) 小児血液・腫瘍学,61-63,診断と治療社,東京,2015.
8 瀧本哲也 : 臨床試験. 日本小児血液・がん学会(編集)小児血液・腫瘍学,332-336,診断と治療社,東京,2015.
9 瀧本哲也 : バイオバンクジャパンと小児がんの検体保存.小児科診療 78, 1723-1727, 2015.
10 瀧本哲也 : AYA世代のがん登録の問題点.小児看護 38, 1434-1437, 2015.

氏名:加藤 承彦

主な論文・総説・著書
1 Kato, T., Yorifuji, T., Yamakawa, M., Inoue, S., Saito, K., Doi, H., and Kawachi, I. (2015). Association of Breastfeeding with Early Childhood Dental Caries: Japanese Population-based Study, BMJ Open, 2015 Mar 20;5(3):e006982.
2 Yamakawa, M., Yorifuji, T., Kato, T., Inoue, S., and Tsuda, T. (2015). Long-term Effects of Breastfeeding on Children's Hospitalization for Respiratory Tract Infections and Diarrhea in early childhood in Japan, Maternal and Child Health Journal, Feb 6.
3 Yamakawa, M., Yorifuji, T., Kato, T., Yamauchi, Y., and Doi, H. (2014). Breastfeeding and Hospitalization for Asthma in Early Childhood: A Nationwide Longitudinal Survey in Japan, Public Health Nutrition, Nov 6:1-6.
4 Yorifuji, T., Kato, T., Tokibnobu, A., Yamakawa, M., Tsuda, T., and Sanada, S. (2014). Intrauterine Exposure to Methylmercury and Neurocognitive Functions-Minamata Disease, Archives of Environmental and Occupational Health, June 27:0.
5 Yorifuji, T., Kubo, T., Yamakawa, M., Kato, T., Inoue, S., and Doi, H. (2014). Breastfeeding and Behavioral Development: A Nationwide Longitudinal Survey in Japan, Journal of Pediatrics, 164(5), 1019-1025.
6 Kato, T., Yorifuji, T., Inoue, S., Yamakawa, M., Doi, H., and Kawachi, I. (2013). Preterm Births and Child Health and Development: Japanese Population-based Study, Journal of Pediatrics, 163(6), 1578-1584.
7 Yorifuji, T., Kashima, S., Tokinobu, A., Kato, T., and Tsuda, T. (2013). Regional impact of exposure to a polychlorinated biphenyls and polychlorinated dibenzofurans mixture from contaminated rice oil on stillbirth rate and secondary sex ratio, Environment International, 59, 12-15.
8 Kato, T., Yorifuji, T., Inoue, S., Doi, H., and Kawachi, I. (2013). Association of Birth Length and Risk of Hospitalization among Full-term Babies in Japan, Paediatric and Perinatal Epidemiology, 27(4), 361-70.
9 Yamakawa, M., Yorifuji, Y., Inoue, S., Kato, T., and Doi, H. (2013). Breastfeeding and Obesity among Schoolchildren: A Nationwide Longitudinal Survey in Japan, JAMA Pediatrics, 167(10): 919-925.
10 Yorifuji, T., Naruse, H., Kashima, S., Murakoshi, T., Kato, T., Inoue, S., Doi, H., and Kawachi, I. (2012). Trends of Preterm birth and Low Birth Weight in Japan: Contribution of Obstetrical Intervention, BMC Pregnancy and Childbirth, 12, 162.

氏名:森崎 菜穂

主な論文・総説・著書
1 Morisaki N, Isayama T, Samura O, Wada K, Kusuda S. Impact of social factors on fetal and infant survival for deliveries at 22 to 24 weeks of gestation. Archives of Diseases in Childhood. Fetal & Neonatal edition 2017 Aug 28. doi: 10.1136/archdischild-2017-312635. [Epub ahead of print]
2 Morisaki N, Urayama KY, Yoshii K, Subramanian SV, Yokoya S. Ecological analysis of secular trends in low birth weight births and adult height in Japan. J Epidemiology and Community Health. 2017 Aug 19. doi: 10.1136/jech-2017-209266. [Epub ahead of print]
3 Morisaki N, Ogawa K, Urayama KY, Sago H, Sato S, Saito S. Preeclampsia mediates the association between shorter height and increased risk of preterm delivery. International Journal of Epidemiology 2017 June 29. doi: 10.1093/ije/dyx107 [Epub ahead of print]
4 Morisaki N, Nagata C, Jwa SC, Sago H, Saito S, Oken E, Fujiwara T. Pre-pregnancy BMI-specific optimal gestational weight gain for women in Japan. J Epidemiology 2017 May 31. doi: 10.1016/j.je.2016.09.013 [Epub ahead of print]
5 Morisaki N, Ganchimeg T, Vogel J, Zeitlen J, Cecatti JG, Souza JP, Castro CP, Torloni MR, Ota E, Mori R, Dolan SM, Tough S, Mittal S, Bataglia V, Yadamsuren B, Kramer MS. Impact of stillbirths on international comparisons of preterm birth rates: A secondary analysis of the WHO multi-country survey of Maternal and Newborn Health. BJOG: international journal of obstetrics and gynaecology 2017 Aug;124(9):1346-1354
6 Morisaki N, Kawachi I, Oken E, Fujiwara T. Parental characteristics can explain why Japanese women give birth to the smallest infants in the United States. Paediatric and Perinatal Epidemiology 2016. Sep;30(5):473-8)
7 Richards JL, Kramer MS, Deb-Rinker P, Rouleau J, Mortensen L, Gissler M, Morken NH, Skjærven R, Cnattingius S, Johansson S, Delnord M, Dolan SM, Morisaki N, Tough S, Zeitlin J, Kramer MR. Temporal Trends in Late Preterm and Early Term Birth Rates in 6 High-Income Countries in North America and Europe and Association With Clinician-Initiated Obstetric Interventions. JAMA. 2016 July 26;316(4):410-9.
8 Fujiwara T, Morisaki N, Honda Y, Sampei M, Tani Y. Chemicals, Nutrition, and Autism Spectrum Disorder: A Mini-Review. Front Neurosci. 2016 Apr 20;10:174.
9 森崎菜穂, 永田知映, 左合治彦, 齋藤滋. 日本人にとっての適切な妊娠中体重増加量の算出. 産婦人科の実際. 2017年 4月号.66 (6) 522-526
10 森崎菜穂, 山岡結衣, 溝口史剛 チャイルド・デス・レビュー~日本での実現に向けて~周産期医学. 2016(5)283-286

氏名:掛江 直子

主な論文・総説・著書
1 Chieko Kurihara, Hideo Kusuoka, Shunsuke Ono, Naoko Kakee, et al: High Rate of Awarding Compensation for Claims of Injuries Related to Clinical Trials by Pharmaceutical Companies in Japan. PLOS ONE 2014; 9(1): e84998.
2 Naoko Tsuji, Naoko Kakee, Yasushi Ishida, et al: Validation of the Japanese version of the Pediatric Quality of Life Inventory (PedsQL) Cancer Module. Health and Quality of Life Outcomes 2011, 9:22. doi: 10.1186/1477-7525-9-22.
3 掛江直子: 海外における新生児・小児の治療の差し控え・中止のガイドライン. 船戸正久編. 新生児・小児医療かかわる人のための看取りの医療. 診断と治療社, 2010: 150-158.
4 掛江直子: 日本における治療の差し控え・中止のガイドライン. 船戸正久編. 新生児・小児医療かかわる人のための看取りの医療. 診断と治療社, 2010: 159-170.
5 Yasushi Ishida, Naoko Sakamoto, Kiyoko Kamibeppu, Naoko Kakee, et al: Late effects and quality of life of childhood cancer survivors: Part 2. Impact of radiotherapy. Int. J Hematol 2010; 92: 95-104.
6 Fujii C, Sato Y, Harada S, Kakee N, et al: M. Attitude to extended use and long-term storage of newborn screening blood spots in Japan. Pediatr Int 2010; 52(3): 393-397.
7 掛江直子: 臨床試験に参加する患児の人権保護(研究倫理). 五十嵐隆・菊池陽編. 小児科臨床ピクシス10. 小児白血病診療, 中山書店, 2009: 176-179.
8 掛江直子, 田中英高, 星井桜子, 他: 小児脳死臓器移植に関するアンケート調査-日本小児科学会会員に対する意識調査2007-. 日本小児科学会雑誌 2009; 113(7): 1181-1193.
9 Hirokazu Sato, Nobue Nakamura, Shohei Harada, Naoko Kakee, et al: Quality of life of young adults with congenital hypothyroidism; Pediatrics International 2009; 51:126-131.
10 掛江直子: 再生医療における倫理的・法的・社会的問題. 綜合臨牀 2009; 58(1) :27-32.

氏名:蓋 若琰(がいじゃくえん)

主な論文・総説・著書
1 Tobe RG*, Martin GR, Li F, Mori R. Should postnatal oximetry screening be implemented nationwide in China? A cost-effectiveness analysis in three regions with different socioeconomic status. International Journal of Cardiology. 2016; 204: 45-7.
2 Tobe RG*. Association between transient newborn hypoglycemia and test proficiency. JAMA Pediatrics. 2016; 170: 297.
3 Mo X, Xu L, Luo H, Wang X, Zhang F, Tobe RG*. Do different parenting styles impact the health and physical growth of “left-behind” preschool-aged children? A cross-sectional study in rural China. European Journal of Public Health. 2016; 26: 18-23.
4 Tobe RG, Mori R, Huang L, et al. Cost-effectiveness analysis of a national neonatal hearing screening program in China: conditions for the scale-up. PLoS ONE.2013; 8: e51990.
5 Tobe RG, Mori R. Use of multiple micronutrient powders for young children’s growth. The Lancet. 2013;382:1171-2.
6 Huang L, Zhang L, Tobe RG, et al. Cost-effectiveness analysis of neonatal hearing screening program in China: should universal screening be prioritized? BMC Health Services Research. 2012; 12: 97.
7 Song P, Tobe RG, Inagaki Y, et al. The management of hepatocellular carcinoma around the world: A comparison of guidelines from 2001 to 2011. Liver Interventional. 2012; 32: 1053-63.
8 Ota E, Tobe-Gai R, Mori R, Farrar D. Antenatal dietary advice and supplementation to increase energy and protein intake. Cochrane Database of Systematic Reviews 2012, Issue 9. Art. No.: CD000032. DOI: 10.1002/14651858.CD000032.pub2.
9 Tobe RG, Mori R, Shinozuka N, et al Birthweight discordance, risk factors and its impact on perinatal mortality among Japanese twins: data from a national project during 2001-2005. Twin Research and Human Genetics 2010; 13: 490-4.
10 Tobe RG, Mori R, Shinozuka N, et al. A nationwide investigation on gestational age specific birthweight and discharge mortality among Japanese twins in general hospitals. Paediatrics and Perinatal Epidemiology. 2010; 25: 228-35.

氏名:永田 知映

主な論文・総説・著書
1 Ganchimeg, T., C. Nagata, J. P. Vogel, N. Morisaki, C. Pileggi-Castro, E. Ortiz-Panozo, K. Jayaratne, S. Mittal, E. Ota, J. P. Souza and R. Mori. "Optimal Timing of Delivery among Low-Risk Women with Prior Caesarean Section: A Secondary Analysis of the Who Multicountry Survey on Maternal and Newborn Health." PLoS One 11, no. 2 (2016): e0149091.
2 Yanaihara, N., Y. Hirata, N. Yamaguchi, Y. Noguchi, M. Saito, C. Nagata, S. Takakura, K. Yamada and A. Okamoto. "Antitumor Effects of Interleukin-6 (Il-6)/Interleukin-6 Receptor (Il-6r) Signaling Pathway Inhibition in Clear Cell Carcinoma of the Ovary." Mol Carcinog, (2015).
3 Rumbold, A., E. Ota, C. Nagata, S. Shahrook and C. A. Crowther. "Vitamin C Supplementation in Pregnancy." Cochrane Database Syst Rev 9, (2015): Cd004072.
4 Nagata, C., H. Tanabe, S. Takakura, C. Narui, M. Saito, N. Yanaihara and A. Okamoto. "Randomized Controlled Trial of Enoxaparin Versus Intermittent Pneumatic Compression for Venous Thromboembolism Prevention in Japanese Surgical Patients with Gynecologic Malignancy." J Obstet Gynaecol Res 41, no. 9 (2015): 1440-8.
5 Suzuki, K., S. Takakura, M. Saito, A. Morikawa, J. Suzuki, K. Takahashi, C. Nagata, N. Yanaihara, H. Tanabe and A. Okamoto. "Impact of Surgical Staging in Stage I Clear Cell Adenocarcinoma of the Ovary." Int J Gynecol Cancer 24, no. 7 (2014): 1181-9.
6 Sasaki, T., H. Nishi, C. Nagata, T. Nagai, T. Nagao, F. Terauchi and K. Isaka. "A Retrospective Study of Urokinase-Type Plasminogen Activator Receptor (Upar) as a Prognostic Factor in Cancer of the Uterine Cervix." Int J Clin Oncol 19, no. 6 (2014): 1059-64.
7 Yamada, K., H. Tanabe, M. Imai, T. Jobo, K. Kudo, H. Fujiwara, C. Nagata, K. Furuya, M. Suzuki, K. Ochiai, T. Tanaka and M. Yasuda. "Feasibility Study of Paclitaxel Plus Carboplatin in Patients with Endometrial Cancer: A Japan Kanto Tumor Board Study (Jktb Trial)." J Obstet Gynaecol Res 39, no. 1 (2013): 311-6.
8 Yanaihara, N., M. S. Anglesio, K. Ochiai, Y. Hirata, M. Saito, C. Nagata, Y. Iida, S. Takakura, K. Yamada, T. Tanaka and A. Okamoto. "Cytokine Gene Expression Signature in Ovarian Clear Cell Carcinoma." Int J Oncol 41, no. 3 (2012): 1094-100.
9 Nagata, C., S. Yanagida, A. Okamoto, A. Morikawa, K. Sugimoto, S. Okamoto, K. Ochiai and T. Tanaka. "Risk Factors of Treatment Discontinuation Due to Uterine Bleeding in Adenomyosis Patients Treated with Dienogest." J Obstet Gynaecol Res 38, no. 4 (2012): 639-44.
10 永田知映, 他. 神田英一郎監訳:初心者のためのロジスティック回帰分析入門. 丸善出版株式会社, 東京, 2012. P33-59.